ESR1 and breast carcinoma: Earlier studies had found that activating PIK3CA mutations occur frequently in estrogen receptor (ER)-positive breast cancers [5], but treatment of such PIK3CA-mutant cancers with potent PI3K inhibitors induces an increase in ER-driven transcriptional programs that contribute to clinical resistance [6].